Overview

Biktarvy for Non-Occupational Post-Exposure Prophylaxis (nPEP)

Status:
Recruiting
Trial end date:
2021-09-01
Target enrollment:
Participant gender:
Summary
Study will evaluate the safety and tolerability of once daily Biktarvy for 28 days for prevention of HIV infection in HIV-1-seronegative adults after high-risk sexual contact. (non-occupational post exposure prophylaxis - nPEP)
Phase:
Phase 4
Details
Lead Sponsor:
Fenway Community Health
Treatments:
Emtricitabine
Emtricitabine tenofovir alafenamide
Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination
Tenofovir